An ambitious new study of pregnancy aims to be a test for health tech; Senate proposal to lower insulin prices would let drugmakers lock in profits.

"If these types of consumer grade sensors can pick up things in real life, I think this study either makes or breaks them in many ways." ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      Wearables are collecting a flood of data. An ambitious new study of pregnancy aims to prove that's valuable for health By Mario Aguilar Alex Hogan/STAT Apple Watches and other wearables are collecting a flurry of pregnancy data. Researchers want to prove that can be valuable in health care. Read More STAT+: With cryptocurrency and NFTs, 'decentralized science' seeks to upend drug industry financing By Allison DeAngelis Adobe New groups hope to break down the closed doors behind which decisions get made on what drug candidates are developed and who gets funding. Read More Opinion: Needed: a clearer explanation of why diversity in clinical trials is important By Arthur L. Caplan Adobe Despite myriad calls for increasing the diversity of clinical trials participants, clear explanations for why that is important are lacking. Read More Sponsor content by ALNYLAM PHARMACEUTICALS "Silencing" the expression of disease-causing genes using RNA interference (RNAi) During gene expression, errors in DNA can result in faulty mRNA that cause or contribute to disease. Alnylam's RNAi therapeutics utilize specially designed small interfering RNA (siRNA) to target and degrade these mRNA, treating disease at source. Learn how. STAT+: Despite fanfare, the FDA's step toward lowering nicotine levels in cigarettes is a very early one By Nicholas Florko Sarah Silbiger/Getty Images While lowering nicotine levels in cigarettes would be a massive deal, the FDA this week only took a first, very small step, toward that goal. Read More Opinion: Signals from monkeypox: Create an external advisory group to start preparing for the next pandemic By Julie L. Swann Pablo Blazquez Dominguez/Getty Images Creating an external advisory group to address disease modeling and interventions is a key step toward planning for the next pandemic. Read More Listen: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict By Damian Garde and Meg Tirrell and Adam Feuerstein This episode we discuss the FDA's decision to ban the sale of Juul Labs and a rumored blockbuster buyout in biotech. Read More STAT+: Congress is closer than ever to formally authorizing ARPA-H. But the details aren't as final as they seem By Lev Facher Greg Nash/AP Congress is closer than ever to formally authorizing ARPA-H. But the debate over its independence is continuing. Read More STAT+: New Senate proposal to lower insulin prices would let drugmakers lock in their current profits By Rachel Cohrs Sarah Silbiger-Pool/Getty Images A new proposal that senators claim would fix insulin pricing would actually allow drugmakers to lock in their current profits. Read More Thursday, June 23, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser